FULCRUM THERAPEUTICS

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

18 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET

20 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 08:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences

09 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET

31 Oct 2023 08:50:33 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference

22 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 Sep 2023 16:30:00 By Nasdaq GlobeNewswire

Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

07 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease

22 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Aug 2023 16:53:28 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023

03 Aug 2023 07:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Chief Financial Officer

03 Aug 2023 06:55:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET

27 Jul 2023 07:00:01 By Nasdaq GlobeNewswire